Gastrointestinal Cancer

The FDA has approved regorafenib (Stivarga) as a second-line treatment for patients with hepatocellular carcinoma (HCC) who have previously received sorafenib (Nexavar).

Andrew Kennedy, MD, physician-in-chief and radiation oncologist at Sarah Cannon Research Institute, discusses the next steps following the SIRFLOX clinical trial for patients with liver-metastatic colorectal cancer (CRC).

Amit Singal, MD, discusses the recent successes in the hepatocellular carcinoma treatment landscape and the challenges that still remain.

Sanjaya K. Satapathy, MD, associate professor, Transplant Hepatology Division of Surgery, Methodist University Hospital Transplant Institute, University of Tennessee Health Sciences Center, discusses preventing recurrence in orthotopic liver transplant recipients with hepatocellular carcinoma.

Bruno Sangro, MD, PhD, head of Hepatology Unit, Internal Medicine Department, Clinica Universidad de Navarra, discusses the safety profile of nivolumab (Opdivo) in advanced hepatocellular carcinoma (HCC).

Jordi Bruix, MD, discusses the success of regorafenib in hepatocellular carcinoma and its impact on the field going forward.

The first-in-class prodrug, mipsagargin (G-202), showed promising antitumor activity and enabled patients with advanced sorafenib-refractory hepatocellular carcinoma to achieve disease stabilization.

Liver-targeting treatment with selective internal radiation therapy more effectively controlled liver tumor progression and was better tolerated in patients with hepatocellular carcinoma, but the therapy did not improve rates of overall or progression-free survival over sorafenib.

Nadine Abi-Jaoudeh, MD, associate professor, Department of Radiological Sciences, director, Research of Interventional Radiology in the Department of Radiological Sciences, University of California Irvine School of Medicine, discusses the combination of tirapazamine (SR-4233) and transarterial embolization in hepatocellular carcinoma (HCC).

Jordi Bruix, MD, head of the Barcelona Clinic Liver Cancer (BCLC) at University of Barcelona, discusses the recent success of regorafenib (Stivarga) in hepatocellular carcinoma (HCC) and its impact on the field.

R. Kate Kelley, MD, associate professor, University of California, San Francisco, discusses biomarkers for immunotherapy in hepatocellular carcinoma.

Log10 alpha fetoprotein level in the blood directly corresponded to the months of posttreatment survival in patients with hepatocellular carcinoma, independent of the type of treatment, regional differences, and disease etiology.

Johanna C. Bendell, MD, director of GI Oncology Research at Sarah Cannon Research Institute, discusses the remaining questions researchers have with regorafenib (Stivarga) for patients with hepatocellular carcinoma (HCC).

Sorafenib-experienced patients with advanced hepatocellular carcinoma had long-term responses to nivolumab of more than 1 year, according to findings from the CheckMate-040 trial.

Jesper Andersen, PhD, associate professor, Biotech and Innovation Centre, University of Copenhagen, discusses the relationship between reduced organic cation transporter-1 (OCT1) and poor response to sorafenib (Nexavar) in hepatocellular carcinoma (HCC) and cholangiocarcinoma.

Spanish researchers raised a red flag regarding observations of unexpected higher rates of hepatocellular carcinoma recurrence following treatment with direct-acting antivirals for hepatitis C virus infection.

David James Pinato, MD, MRCP, PhD, Faculty of Medicine, Department of Surgery and Cancer, NIHR Academic Clinical Lecturer, Imperial College London, discusses a study of intratumor heterogeneity in the regulation of immune-tolerogenic pathways in primary and metastatic hepatocellular carcinoma.

Tomi Jun, MD, Stanford University School of Medicine, discusses the results of a study of cirrhosis and long-term survival in patients with cryptogenic hepatocellular carcinoma.

Nadine Abi-Jaoudeh, MD, discusses a study of tirapazamine and transarterial embolization and the promise of combinations in hepatocellular carcinoma.

MicroRNA-34a, one of the most documented tumor suppressor microRNAs, is being evaluated as a potential therapeutic target in hepatocellular carcinoma.

Higher levels of hepatocytes positive for pERK immunostaining and greater microvascular invasion have emerged as independent prognostic factors of recurrence in patients following sorafenib (Nexavar) treatment for hepatocellular carcinoma.

Nadine Abi-Jaoudeh, MD, associate professor, Department of Radiological Sciences, director, Research of Interventional Radiology in the Department of Radiological Sciences, University of California Irvine School of Medicine, discusses the potential for immunotherapy in advanced hepatocellular carcinoma.

Amira Abdelhamid, assistant lecturer, German University in Cairo, discusses microRNA-34a and natural killer (NK) cells in hepatocellular carcinoma (HCC).

Manish A. Shah, MD, director of gastrointestinal oncology, Weill Cornell Medicine/New York-Presbyterian Hospital, discusses the increase in prevalence of early-onset colorectal cancer (CRC).

A meta-analysis found that patients were at no elevated risk of developing hepatocellular carcinoma after achieving sustained virologic response following treatment with direct-acting antiviral therapy for hepatitis C compared to interferon therapy.